{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 69,
        "end": 73
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 118,
        "end": 122
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 319,
        "end": 328
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 344,
        "end": 348
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 467,
        "end": 471
      }
    },
    {
      "id": "T12",
      "obj": "Chemical",
      "span": {
        "begin": 467,
        "end": 477
      }
    },
    {
      "id": "T8",
      "obj": "Disease",
      "span": {
        "begin": 69,
        "end": 88
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 118,
        "end": 127
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 344,
        "end": 363
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 408,
        "end": 454
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "25242669_6",
  "text": "PATIENTS AND METHODS : The IRENE ( Iressa RE-challenge in advanced , EGFR -mutated NSCLC patients who responded to an EGFR -TKI used as first-line or previous treatment ) ( Dutch association for pulmonologists [ NVALT ] -16 ) trial is a multicenter , open-label , single-arm , single-stage , phase II study to evaluate gefitinib rechallenge in EGFR -mutated NSCLC patients who were previously treated with a TKI followed by a subsequent line of treatment ( excluding EGFR -TKIs ) ."
}
